Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer

Chantal C H J Kuijpers, Cathy B. Moelans, Henk Jan Van Slooten, Anja Horstman, John W J Hinrichs, Shaimaa Al-Janabi, Paul J. Van Diest, Mehdi Jiwa

Research output: Contribution to journalArticle

Abstract

Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p

Original languageEnglish (US)
Article numbere82018
JournalPLoS One
Volume8
Issue number12
DOIs
StatePublished - Dec 4 2013
Externally publishedYes

Fingerprint

Chromogenics
Multiplex Polymerase Chain Reaction
value added
breast neoplasms
in situ hybridization
In Situ Hybridization
Amplification
Breast Neoplasms
Testing
testing
Validation Studies
Pathology
methodology
therapeutics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Kuijpers, C. C. H. J., Moelans, C. B., Van Slooten, H. J., Horstman, A., Hinrichs, J. W. J., Al-Janabi, S., ... Jiwa, M. (2013). Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS One, 8(12), [e82018]. https://doi.org/10.1371/journal.pone.0082018

Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. / Kuijpers, Chantal C H J; Moelans, Cathy B.; Van Slooten, Henk Jan; Horstman, Anja; Hinrichs, John W J; Al-Janabi, Shaimaa; Van Diest, Paul J.; Jiwa, Mehdi.

In: PLoS One, Vol. 8, No. 12, e82018, 04.12.2013.

Research output: Contribution to journalArticle

Kuijpers, CCHJ, Moelans, CB, Van Slooten, HJ, Horstman, A, Hinrichs, JWJ, Al-Janabi, S, Van Diest, PJ & Jiwa, M 2013, 'Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer', PLoS One, vol. 8, no. 12, e82018. https://doi.org/10.1371/journal.pone.0082018
Kuijpers CCHJ, Moelans CB, Van Slooten HJ, Horstman A, Hinrichs JWJ, Al-Janabi S et al. Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS One. 2013 Dec 4;8(12). e82018. https://doi.org/10.1371/journal.pone.0082018
Kuijpers, Chantal C H J ; Moelans, Cathy B. ; Van Slooten, Henk Jan ; Horstman, Anja ; Hinrichs, John W J ; Al-Janabi, Shaimaa ; Van Diest, Paul J. ; Jiwa, Mehdi. / Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{813b0014d1234729a51c36a04594136a,
title = "Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer",
abstract = "Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100{\%} concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8{\%} of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p",
author = "Kuijpers, {Chantal C H J} and Moelans, {Cathy B.} and {Van Slooten}, {Henk Jan} and Anja Horstman and Hinrichs, {John W J} and Shaimaa Al-Janabi and {Van Diest}, {Paul J.} and Mehdi Jiwa",
year = "2013",
month = "12",
day = "4",
doi = "10.1371/journal.pone.0082018",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer

AU - Kuijpers, Chantal C H J

AU - Moelans, Cathy B.

AU - Van Slooten, Henk Jan

AU - Horstman, Anja

AU - Hinrichs, John W J

AU - Al-Janabi, Shaimaa

AU - Van Diest, Paul J.

AU - Jiwa, Mehdi

PY - 2013/12/4

Y1 - 2013/12/4

N2 - Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p

AB - Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p

UR - http://www.scopus.com/inward/record.url?scp=84891893438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891893438&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0082018

DO - 10.1371/journal.pone.0082018

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e82018

ER -